Table 5. Distant disease-free and breast cancer-specific survival.

	HR <6 years after diagnosis		HR ⩾6 years after diagnosis
	Univariate	Multivariate	Univariate	Multivariate
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Distant disease-free survival
All patients	1.02 (0.78–1.33)	1.08 (0.83–1.42)a	2.15 (1.45–3.18)	2.65 (1.79–3.93)a
No adjuvant chemotherapy	0.90 (0.64–1.27)	0.98 (0.69–1.38)b	1.98 (1.19–3.28)	2.31 (1.39–3.83)b
Adjuvant chemotherapy	1.38 (0.90–2.13)	1.41 (0.91–2.16)c	3.64 (1.94–6.81)	4.54 (2.41–8.56)c
Anthracycline-based chemotherapy	1.58 (0.92–2.72)	1.59 (0.92–2.75)c	3.64 (1.55–8.55)	4.16 (1.69–10.22)c
Nonanthracycline-based chemotherapy	1.23 (0.61–2.50)	1.16 (0.57–2.35)c	3.76 (1.49–9.47)	4.73 (1.85–12.09)c
No adjuvant hormonal therapy	1.01 (0.75–1.36)	1.08 (0.80–1.45)a	2.43 (1.59–3.71)	2.88 (1.88–4.41)a
Adjuvant hormonal therapy	1.22 (0.66–2.23)	1.36 (0.74–2.51)a	2.79 (1.01–7.73)	3.24 (1.16–9.03)a
Breast cancer-specific survival
All patients	0.96 (0.68–1.35)	1.00 (0.71–1.41)b	1.75 (1.20–2.54)	2.05 (1.41–2.99)b
No adjuvant chemotherapy	0.92 (0.60–1.41)	1.00 (0.65–1.53)b	1.68 (1.03–2.73)	2.03 (1.25–3.32)b
Adjuvant chemotherapy	1.10 (0.61–1.97)	1.05 (0.59–1.88)b	2.33 (1.29–4.21)	2.55 (1.40–4.64)b

Abbreviations: CI=confidence interval; HR=hazard ratio.

^aAdjusted for tumour size and chemotherapy, and other covariates had an impact of <10% on the HR.

^bAdjusted for tumour size, and other covariates had an impact of <10% on the HR.

^cAdjusted for tumour size and hormonal therapy, and other covariates had an impact of <10% on the HR.